Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO 2022 Highlights
Survey Results Provide Insights into Biosimilar Use at Cancer Centers
By
Wayne Kuznar
Biosimilars
,
ASCO 2022 Highlights
February 2023, Vol 14, No 1
Results from a survey of cancer centers revealed that 66% of responding institutions had a biosimilar interchangeability policy in place, but barriers to adoption remain an issue.
Read Article
Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models
By
Wayne Kuznar
Biosimilars
,
ASCO 2022 Highlights
February 2023, Vol 14, No 1
Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution.
Read Article
Trastuzumab Deruxtecan Is a New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
By
Wayne Kuznar
ASCO 2022 Highlights
,
Breast Cancer
August 2022, Vol 13, No 4 Online Only
Targeting
HER2
with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with
HER2
-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Read Article
First-Line Treatment with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
By
Phoebe Starr
ASCO 2022 Highlights
,
Rectal Cancer
August 2022, Vol 13, No 4 Online Only
First-line treatment with dostarlimab-gxly (Jemperli), a PD-1 inhibitor, achieved complete responses (CRs) in 100% of a subset of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, sparing them surgery, chemotherapy, and radiation, as of the latest follow-up.
Read Article
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
By
Phoebe Starr
ASCO 2022 Highlights
August 2022, Vol 13, No 4 Online Only
According to data from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to experience delays or disruptions in cancer treatment during the pandemic.
Read Article
Acalabrutinib Shows Promise in Patients with MZL
By
Phoebe Starr
ASCO 2022 Highlights
August 2022, Vol 13, No 4 Online Only
Treatment with acalabrutinib (Calquence) elicited a complete or partial response in more than 50% of patients with relapsed or refractory marginal zone lymphoma (MZL), according to interim results of a phase 2 study.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma